Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi anemia patient.

Journal of pediatric hematology/oncology - 1 Mar 2014

Yeo Crystal J J, Gilman Andrew L

Abstract excerpt

Biallelic BRCA2 mutations occur in 2% of patients with Fanconi anemia and are associated with a high risk of acute leukemia at an early age and a poor prognosis. For the first time, we report the use of interleukin-2 to stimulate a graft-versus-leukemia effect and induce complete remission in a patient with BRCA2 Fanconi anemia and refractory acute myelogenous leukemia, suggesting the potential of immunotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Child, Preschool
Share to Fanconi Anemia

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Hematopoietic Stem Cell Transplantation

Share to Interleukin-2

Share to Leukemia, Myeloid, Acute

Share to Mutation

Source

Identifiers

PMID: 23619121
DOI: 10.1097/MPH.0b013e31828e5c56

Genes

BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Interleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi anemia patient.PMID 23619121Read ↗

Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.Semantic proximity Read ↗

Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.Semantic proximity Read ↗

Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.Semantic proximity Read ↗

Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.Semantic proximity Read ↗

Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.Semantic proximity Read ↗

Hematopoietic stem cell functional failure in interleukin-2-deficient mice.Semantic proximity Read ↗

Interleukin-2-induced lymphoproliferative responses.Semantic proximity Read ↗

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.Semantic proximity Read ↗

Recent approaches to induction of cytotoxic lymphocytes against leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.